Brain scan clues could help tell two blood vessel diseases apart
NCT ID NCT05486897
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at brain scans from 315 people with two types of small vessel disease: cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy (HA). Researchers wanted to see if the pattern of white matter changes around the brain's fluid-filled spaces could help tell the two conditions apart using standard MRI tools. The goal is to make diagnosis easier in everyday medical practice.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors more easily distinguish between two types of small vessel disease using standard brain scans.
- What could go wrong
- This is an observational study that looks at past data, so it cannot prove cause and effect. The results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
315 people
The number who actually took part.
- Started
-
Sep 2022
- Finished
-
Dec 2023
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
CAA and HA patients, managed at Nîmes University Hospital between January 2015 and March 2022
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: CAA and HA patients, managed at Nîmes University Hospital between January 2015 and March 2022. Exclusion Criteria: CAA and HA patients, treated at the CHU of Nîmes between January 2015 and March 2022, not objecting to the use of their health data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cerebral amyloid angiopathy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Nîmes
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can olive oil and walnuts shield the brain from stroke and memory loss?
- Brain scan study reveals hidden differences in two common blood vessel diseases
- Your digital twin could help prevent another stroke
- 500-Patient study aims to unlock secrets of brain bleeding disease
- Scientists hunt for biomarkers to predict brain vessel disease
- Eye injection could spot hidden brain bleeding risk